Researchers in the lab of Jean Cook, Ph.D., chair and professor in the Department of Biochemistry and Biophysics, have identified the cellular processes that occur when you take a cancer drug meant to ...
This study presents a comprehensive investigation into the prognostic significance of CCCRGs in HCC. Notably, our research provides the first mechanistic evidence that CENPI promotes HCC malignant ...
In a new paper published in Cancer Research, researchers at MUSC Hollings Cancer Center have shown that targeting a protein called TACC3 (transforming acidic coiled-coil containing protein 3) can ...
Natural killer (NK) cells play an important role in the innate immune response to cancer and viral infections, and their presence in tumors correlates with improved patient outcomes in a variety of ...
The ability of mutations to cause cancer depends on how fast they force cells to divide, Sinai Health researchers have found. The study, led by Dr. Rod Bremner, a Senior Investigator at the ...
Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells more effectively. Their strategy targets a hidden “off switch” that tumors ...
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study Immune checkpoint blockers ...
The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results